About this trial
To assess whether changes in electrical impedance - measured using an electrical impedance tomography (EIT) chest belt - can be used to derive changes in pulmonary artery pressure (PAP) in critically ill patients when compared to invasive gold-standard PAP measured using pulmonary artery catheter (PAC).
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Age ≥ 18-year-old.
Intubated patients in the ICU with clinical decision to monitor PAP and cardiac output using a PAC.
Disqualifiers
Patients with implanted or external thoracic electronic devices (e.g., pacemaker) or thoracic metal implants.
Known pregnancy or lactating patients.
Open lung injuries or pneumothorax.
Open wounds, drainages, burns or rashes of the upper thorax.
Trial population
For this study the investigators plan to enroll 28 patients with complete datasets for evaluation of PAP derived by PAC and EIT for a minimum duration of 4 hours in the ICU at Inselspital (Bern) with clinical decision to monitor PAP using a PAC.
Trial design
Case-control
Prospective
Treatments tested in this trial
Electrical impedance tomography
DeviceIn addition to routine critical care with a pulmonary artery catheter already in place (PAC), an electrical impedance tomography (EIT) belt will be placed in patients enrolled in this study. Data will be analyzed offline and clinical trajectory and/or decisions will not be impacted by this additional monitoring. EIT is a non-invasive, safe, and radiation-free medical imaging modality.
Treatment groups
Trial outcomes
Primary outcomes
Mean difference between EIT-derived and PAC-measured changes in pulmonary artery pressure
The primary outcome is the difference - expressed as mean and standard deviation (SD) - between changes in EIT-derived pulmonary artery pressure (ΔPAP\_EIT), derived from changes in the pulmonary pulse arrival time, and changes in pulmonary artery catheter-based pulmonary artery pressure (ΔPAP\_PAC). This will be measured over recording periods of up to 48 hours.
Secondary outcomes
Data acceptance rate
Data acceptance rate, i.e., the percentage of total recording duration during which lung EIT signals show pulmonary pressure morphology and thus allow to estimate EIT-derived PAP values.
Concordance rate (%) of directional changes in pulmonary artery pressure between EIT and PAC measurements (Trending ability)
The trending ability will be assessed using four quadrant plot analysis to calculate the concordance rate between EIT-derived and PAC-measured pulmonary artery pressure changes. The concordance rate is defined as the percentage of data points in which both methods agree on the direction of change (increase or decrease) in pulmonary artery pressure.
Accuracy and trending ability of EIT-derived cardiac output compared to PAC measurements
The difference between EIT-derived cardiac output (CO\_EIT) and pulmonary artery catheter-based cardiac output (CO\_PAC) will be calculated. This will be expressed as mean difference ± standard deviation in L/min. The ability of EIT to track changes in cardiac output over time will be evaluated by comparing directional changes in CO\_EIT with corresponding changes in CO\_PAC. This will be reported as the percentage of concordant directional changes between the two methods.
Agreement between EIT-derived and ventilator-measured respiratory parameters
This outcome assesses the ability of EIT to measure key respiratory parameters compared to the mechanical ventilator measurements. The difference between EIT-derived tidal volume and ventilator-measured tidal volume as well as the difference between EIT-derived respiratory rate and ventilator-measured respiratory rate will be calculated and expressed as mean difference ± standard deviation. Other ventilation-related parameters: Additional parameters such as end-expiratory lung volume changes or regional ventilation distribution may also be assessed, depending on the capabilities of the EIT system and the available ventilator data.
Sponsors and contacts
Click on the lead sponsor to view all of their trials.
Insel Gruppe AG, University Hospital Bern
Lead sponsor
CSEM Centre Suisse d'Electronique et de Microtechnique SA - Recherche et Developpement
Collaborator